KöhlerG., & MilsteinC. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, London256, 495–497.
3.
National Research Council. (1991). Committee on Infectious Diseases of Mice and Rats.397 pp. Washington, DC, USA: National Academy Press.
4.
CoxJ.C. (1977). Altered immune responsiveness associated with Encephalitozoon cuniculi infection in rabbits. Infection and Immunity15, 392–395.
5.
KraftV., DeenyA.A., BlanchetH.M., BootR., HansenA.K., HemA., van HerckH., KunstýrI., MiliteG., NeedhamJ.R., NicklasW., PerrotA., RehbinderC., RichardY., & de VroeyG. (1994). Recommendations for the health monitoring of mouse, rat, hamster, guinea-pig and rabbit breeding colonies. Report of the Federation of European Laboratory Animal Science Accociations (FELASA) Working Group on Animal Health. Laboratory Animals28, 1–12.
6.
RehbinderC., BaneuxP., ForbesD., van HerckH., NicklasW., RugayaZ., & WinklerG. (1996). FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea-pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health. Laboratory Animals30, 193–208.
7.
KnightP.A., & LuckenR.N. (1979). The effects of laboratory animal diets on the potency tests of bacterial vaccines. Developments in Biological Standardization45, 143–149.
ZalcmanS., Minkiewicz-JandaA., RichterM., & AnismanH. (1988). Critical periods associated with stressor effects on antibody titers and on the plaque-forming cell response to sheep red blood cells. Brain Behaviour in Immunology2, 254–266.
10.
WilsonM.S., BergeW., MaessJ., MahouyG., NatoffI., NevalainenT., van ZutphenL.F.M., & ZaninelliP. (1995). FELASA recommendations on the education and training of persons working with laboratory animals: categories A and C. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Education. Laboratory Animals29, 121–131.
11.
Council of Europe (1986). European Convention for the Protection of Vertebrate Animals Used for the Experimental and Other Scientific Purposes, 51 pp. Strasbourg, France: Council of Europe.
12.
EEC (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European CommunitiesL358, 1–29.
13.
HanlyW.C., ArtwohlJ.E., & BennettB.T. (1995). Review of polyclonal antibody production procedures in mammals and poultry. ILAR Journal37, 93–118.
14.
SchadeR., StaakC., HendriksenC.F.M., ErhardM., HuglH., KochG., LarssonA., Poll-mannW., van RegenmortelM., RijkeE., SpielmannH., SteinbuschH., & StraughanD. (1996). The production of avian (egg yolk) antibodies: IgY. The report and recommendations of ECVAM workshop 21. ATLA24, 925–934.
15.
Bundesamt für Veterinärwesen (1998). Fachgerechte und tierschutzkonforme Antikörpergewinnung in Kaninchen, Hühnern und Labornagetieren (Production of antibodies in rabbits, chickens and rodents according to the principles of animal welfare and laboratory animal science), 13 pp. Publication No. 800.116–3.04. Bern, Switzerland: BVET.
16.
HauJ. (1989). The Danish guidelines. In Danish State Inspectorate Annual Report 1989, pp. 66–70. Copenhagen, Denmark: Animal Experiments Inspectorate.
17.
ClaassenE., & BoersmaW.J.A. (1992). Characteristics and practical use of new generation adjuvants as an acceptable alternative for Freund's complete adjuvant. Research in Immunology143, 475–582.
18.
Stewart-TullD.E.S. (1995). The Theory and Practical Application of Adjuvants, 380 pp. Chichester, UK: John Wiley & Sons.
19.
VogelF.R., & PowellM.F. (1995). A compendium of vaccine adjuvants and excipients. In Vaccine Design: The Subunit and Adjuvant Approach (ed. PowellM.F., & NewmanM. J.), pp. 141–228. New York, USA: Plenum Press.
20.
CoxJ.C., & CoulterA.R. (1997). Adjuvants: a classification and review of their modes of action. Vaccine15, 248–256.
21.
DroualR., BickfordA.A., CharltonB.R., & KuneyD.R. (1990). Investigation of problems associated with intramuscular breast injection of oil-adjuvanted killed vaccines in chickens. Avian Diseases34, 473–478.
22.
NicklasW., CusslerK., & HartingerJ. (1997). Tierschutzaspekte bei der Immunisierung von Versuchstieren (Animal welfare aspects in the immunisation of laboratory animals), 6 pp. Bonn, Germany: Tierärztliche Vereinigung für den Tierschutz.
23.
HerbertW.J. (1978). Mineral-oil adjuvants and the immunisation of laboratory animals. In Handbook of Experimental Immunology, 3rd edn (ed. WeirD.M.), pp. A3.1–3.15. Oxford, UK: Blackwell.
24.
GoudieR.B., HorneC.H., & WilkinsonP.C. (1966). A simple method for producing antibody specific to a single selected diffusible antigen. Lancet7475, 1224–1226.
25.
NilssonB.O., & LarssonA. (1992). Inert carriers for immunization. Research in Immunology143, 553–557.
26.
IwarssonK., LindbergL., & WallerT. (1994). Common non-surgical techniques and procedures. In Handbook of Laboratory Animal Science, Vol. 1, Selection and Handling of Animals in Biomedical Research (ed. SvensenP., & HauJ.), pp. 229–272. Boca Raton, FL, USA: CRC Press.
27.
van ZutphenL.F.M., BaumansV., & BeynenA.C. (1993). Principles of Laboratory Animal Science, 389 pp. Amsterdam, The Netherlands: Elsevier.
28.
BomfordR. (1980). The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clinical and Experimental Immunology39, 426–434.
29.
JacksonL.R., & FoxJ.G. (1995). Institutional policies and guidelines on adjuvants and antibody production. ILAR Journal37, 141–152.
30.
CCAC (1991). CCAC Guidelines on Acceptable Immunological Procedures, 2 pp. Ottawa, Ontario, Canada: CCAC.
31.
VPHI (1993). Code of Practice for the Immunisation of Laboratory Animals, 5 pp. Rijswijk, The Netherlands: Veterinary Public Health Inspectorate.
32.
BVA/FRAME/RSPCA/UFAW (1993). Joint Working Group on Refinement: removal of blood from laboratory mammals and birds. Laboratory Animals27, 1–22.
33.
McGuillM.W., & RowanA.N. (1989). Biological effects of blood loss: implication for sampling volumes and techniques. ILAR News31, 5–20.
34.
MortonD.B., & GriffithsP.H.M. (1985). Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Veterinary Record116, 431–436.
35.
BarclayR.J., HerbertW.J., & PooleT.B. (1988). The Disturbance Index: A Behavioural Method of Assessing the Severity of Common Laboratory Procedures on Rodents. Animal Welfare Research Report No 2, 36 pp. Potters Bar, Herts., UK: UFAW.
36.
Jansen van ‘t LandC., & HendriksenC.F.M. (1995). Change in locomotor activity pattern in mice: a model for recognition of distress?Laboratory Animals29, 286–293.
37.
BulthuisR.J.A., BergmanA.F., NijessenS., SchlingmannF., TolboomJ., RemieR., Van de WeerdH.A., Van LooP.L.P., BaumansV., & van ZutphenL.F.M. (1997). Automated behaviour classification: the LABORAS project. In Harmonization of Laboratory Animal Husbandry (ed. O'DonoghueP.N.), pp. 17–18. London, UK: Royal Society of Medicine Press.
38.
HarlowE., & LaneD. (1988). Adjuvants. In Antibodies: A Laboratory Manual, pp. 96–124. New York, USA: Cold Spring Harbor Laboratory.
39.
TamJ.P. (1988). Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proceedings of the National Academy of Sciences USA85, 5409–5413.
40.
ChaiS.K., ClavijoP., TamJ.P., & ZavalaF. (1992). Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. Journal of Immunology149, 2385–2390.
41.
ReedR.C., Louis-WilemanV., CosmaiE.V., FangS., JueD.L., WohlhueterR.M., HunterR.L., & LalA.A. (1997). Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. Vaccine15, 482–488.
42.
GlennG.M., RaoM., MatyasG.R., & RayC.R. (1998). Skin immunisation made possible by cholera toxin. Nature, London391, 851.
43.
WinterG., GriffithsA.D., HawkinsR.E., & HoogenboomH.R. (1994). Making antibodies by phage display technology. Annual Review of Immunology12, 433–455.
44.
de KruifJ., van der Vuurst de VriesA.R., CilentiL., BoelE., van EwijkW., & LogtenbergT. (1996). New perspectives on recombinant human antibodies. Immunology Today17, 453–455.
45.
VaughanT.J., WilliamsA.J., PritchardK., OsbournJ.K., PopeA.R., EarnshawJ.C., McCaffertyJ., HoditsR.A., WiltonJ., & JohnsonK.S. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunised phage display library. Nature Biotechnology14, 309–314.
46.
Grumstrupp-ScottJ., & GreenhouseD.D. (1988). NIH intramural recommendations for the research use of complete Freund's adjuvant. ILAR News30, 9.
47.
Home Office Inspectorate. (1991). Antibody production: advice on protocols for minimal severity. In Report of the Animal Procedures Committee for 1991, p. 26. London, UK: HMSO.
48.
Swedish National Board for Laboratory Animals. (1994). General recommendations of the National Board for Laboratory Animals on the treatment of certain matters relating to ethical reviews of the use of animals for scientific purposes (LSFS/Statute book of the National Board of Agriculture/1990: 22 & 23, Subject No. L29). In Provisions and General Recommendations Relating to the Use of Animals for Scientific Purposes (ed. LundgrenO.), pp. 46–49. Stockholm, Sweden: Karl Olov Öster
49.
SCAW (1989). Scientists Center for Animal Welfare: guidelines on immunological procedures. SCAW Newsletter11, 2–6.
50.
ANZCCART (1995). The Use of Immuno-adjuvants in Animals in Australia and New Zealand, 27 pp. Glen Osmond, Australia: ANZCCART.
51.
ATBW. (1998). Empfehlungen über das Immunisieren von Versuchstieren, 1 p. Heidelberg, Germany: Arbeitsgemeinschaft der Tierschutzbeauftragten in Baden-Württemberg.
52.
HerbertW.J., & KristensenF. (1986). Laboratory animal techniques for immunology. In Handbook of Experimental Immunology, Vol. 1, Immunology — Laboratory Manuals (ed. WeirD.M.), pp. 133.1–133.13. Oxford, UK: Blackwell.
53.
BaumansV., ten BergR.G.M., BertensA.P.M.G., HackbarthH.J., & TimmermanA. (1993). Experimental techniques. In Principles of Laboratory Animal Science (ed. van ZutphenL.F.M., BaumansV., & BeynenA.C.), pp. 299–318. Amsterdam, The Netherlands: Elsevier.
54.
de LeeuwW.A., & De GreeveP. (1997). Production of polyclonal and monoclonal antibodies in The Netherlands. In Animal Alternatives, Welfare and Ethics (ed. van ZutphenL.F.M., & BallsM.), pp. 1053–1059. Amsterdam, The Netherlands: Elsevier.
55.
BVA/FRAME/RSPCA/UFAW (1993). Joint Working Group on Refinement. Removal of blood from laboratory mammals and birds. Laboratory Animals27, 1–22.
56.
McGuillM.W., & RowanA.N. (1989). Biological effects of blood loss: implication for sampling volumes and techniques. ILAR News31, 5–20.
57.
Stewart-TullD.E.S. (1995). The Theory and Practical Application of Adjuvants, 380 pp. Chichester, UK: John Wiley & Sons.
58.
SmithD.E., O'BrienM.E., PalmerV.J., & SadowskiJ.A. (1992). The selection of an adjuvant emulsion for polyclonal antibody production using a low molecular weight antigen in rabbits. Laboratory Animal Science42, 599–601.
59.
LeenaarsP.P.A.M., KoedamM.A., WesterP.W., BaumansV., ClaassenE., & HendriksenC.F.M. (1998). Assessment of side-effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Laboratory Animals32, 387–406.
60.
EC (1995). Commission Regulation (EC) No. 2796/95 of 4 December 1995 amending Annex II of Council Regulation (EEC) No. 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance). Official Journal of the European CommunitiesL290, 1–4.
61.
GuptaR.K., RelyveldE.H., LindbladE.B., BizziniB., Ben-EfraimS., & GuptaC.K. (1993). Adjuvants: a balance between toxicity and adjuvanticity. Vaccine11, 293–306.
62.
CollierL.H., PolakoffS., & MortimerJ. (1979). Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet8131, 1364–1367.
63.
BomfordR. (1980). The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clinical and Experimental Immunology39, 426–434.
64.
MannhalterJ.W., NeychevH.O., ZlabingerG.J., AhmadR., & EiblM.N. (1985). Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clinical and Experimental Immunology61, 143–151.
65.
LindbladE.B. (1995). Aluminium adjuvants. In The Theory and Practical Application of Adjuvants (ed. Stewart-TullD.E.S.), pp. 21–35. Chichester, UK: John Wiley & Sons.
66.
WarrenH.S., VogelF.R., & ChedidL.A. (1986). Current status of immunological adjuvants. Annual Review of Immunology4, 369–418.
67.
GrubhoferN. (1995). An adjuvant formulation based on N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with dimethyldioctadecylammonium chloride and zinc-L-proline complex as synergists. Immunology Letters44, 19–24.
68.
VerheulA.F.M., & SnippeH. (1992). Non-ionic block polymer surfactants as immunological adjuvant. Research in Immunology143, 512–519.
69.
HilgersL.A.T., & SnippeH. (1992). DDA as an immunological adjuvant. Research in Immunology143, 494–503.
70.
DalsgaardK., LovgrenK., & Stewart-TullD.E.S. (1995). Immune stimulating complexes with Quil A. In The Theory and Practical Application of Adjuvants (ed. Stewart-TullD.E.S.), pp. 129–144. Chichester, UK: John Wiley & Sons.
71.
MoreinB., SundquistB., HöglundS., DalsgaardK., & OsterhausA.D.M.E. (1984). ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, London308, 457–459.
72.
BuitingA.M.J., Van RooijenN., & ClaassenE. (1992). Liposomes as antigen carriers and adjuvants in vivo. Research in Immunology143, 541–548.
73.
AlvingC.R. (1997). Liposomes as adjuvants for vaccines. In New Generation Vaccines, 2nd edn (ed. LevineM.M., WoodrowG.C., KaperJ.B., & CobonG.S.), pp. 207–213. New York, USA: Marcel Dekker.
74.
BoersmaW.J.A., BogaertsW.J.C., BianchiA.T.J., & ClaassenE. (1992). Adjuvant properties of stable water-in-oil emulsions: evaluation of the experience with Specol. Research in Immunology143, 503–512.
75.
CampbellJ.B., & PeerbayeY.A. (1992). Saponin. Research in Immunology143, 526–530.